Please Wait
Applying Filters...
Menu
$ API Ref.Price (USD/KG) : 836Xls
Filters Filter
Cross PopUp
FILTER :

filter clear-filterReset all filters

01 5Alphagan/Combigan

02 2Xalabrands

PharmaCompass

01

02

03

Brand Name : Alphagan/Combigan

arrow
Antibody Engineering
Not Confirmed

Timolol Maleate

Main Therapeutic Indication : Ophthalmology

Currency : USD

2022 Revenue in Millions : 346

2021 Revenue in Millions : 529

Growth (%) : -35

Abbvie Company Banner

04

Brand Name : Alphagan/Combigan

arrow
Antibody Engineering
Not Confirmed

Timolol Maleate

Main Therapeutic Indication : Ophthalmology

Currency : USD

2023 Revenue in Millions : 272

2022 Revenue in Millions : 346

Growth (%) : -21

Abbvie Company Banner

05

Brand Name : Alphagan/Combigan

arrow
Antibody Engineering
Not Confirmed

Timolol Maleate

Main Therapeutic Indication : Ophthalmology

Currency : USD

2019 Revenue in Millions : 522

2018 Revenue in Millions : 551

Growth (%) : -5

Abbvie CB

06

Brand Name : Xalabrands

Timolol

arrow
Antibody Engineering
Not Confirmed

Brand Name : Xalabrands

arrow
Antibody Engineering
Not Confirmed

Timolol

Main Therapeutic Indication : Ophthalmology

Currency : USD

2022 Revenue in Millions : 195

2021 Revenue in Millions : 226

Growth (%) : -14

blank

07

Brand Name : Xalabrands

Timolol

arrow
Antibody Engineering
Not Confirmed

Brand Name : Xalabrands

arrow
Antibody Engineering
Not Confirmed

Timolol

Main Therapeutic Indication : Ophthalmology

Currency : USD

2023 Revenue in Millions : 193

2022 Revenue in Millions : 195

Growth (%) : -1

blank